secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-067569
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics initiates strategic alternatives review, hires Piper Sandler
--------------------------------------------------------------------------------

- Feb 24, 2026: Werewolf (HOWL) announces exploration of strategic alternatives including sale, merger, or licensing.
- Hired Piper Sandler & Co. as exclusive financial advisor to assist in the strategic evaluation.
- CEO Dan Hicklin cites INDUKINE and INDUCER platforms and clinical-stage candidates as core assets.
- No defined timeline; company will not disclose further unless board approves specific action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526067569/0001193125-26-067569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526067569/d808115d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-067569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer